Cilostazol use and calf muscle pathophysiology in people with peripheral artery disease
Published online on June 11, 2026
Abstract
Vascular Medicine, Volume 31, Issue 4, Page 482-492, August 2026.
Introduction:Cilostazol is a phosphodiesterase 3 (PDE3) inhibitor and is one of the only approved medications shown to improve walking performance in patients with peripheral artery disease (PAD). However, its effects on skeletal muscle pathophysiology ...
Introduction:Cilostazol is a phosphodiesterase 3 (PDE3) inhibitor and is one of the only approved medications shown to improve walking performance in patients with peripheral artery disease (PAD). However, its effects on skeletal muscle pathophysiology ...